Please assess the completion status of the following clinical trial:

Trial Title: Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Male Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent prior to performance of any trial-related activity~* Man ≥20 years of age~* Nocturia symptoms present for ≥6 months prior to trial entry at Visit 1~* ≥2 nocturnal voids at the end of screening period prior to Visit 2~* Nocturnal polyuria at the end of screening period prior to Visit 2~* Bothered by nocturia on the Hsu 5-point Likert bother scale at Visit 1 and Visit 2~* Has given agreement about contraception during the trial~Exclusion Criteria:~* Evidence of any significant voiding dysfunction resulting in abnormally low bladder capacity at the end of the screening period prior to Visit 2~* History or evidence of significant obstructive sleep apnoea~* History or diagnosis of any of the following urological diseases at Visit 1:~  * Interstitial cystitis or bladder pain disorder~ * Suspicion of moderate or severe benign prostate hyperplasia (BPH), defined as international prostate symptom score (IPSS) ≥8 points and:~    * Urinary flow \<5 mL/s or~   * Post-void residual volume \>150 mL~ * Stress urinary incontinence or mixed incontinence, where stress incontinence is the predominant component based on prior history~ * Chronic pelvic pain syndrome~* Surgical treatment, including transurethral resection, for bladder outlet obstruction (BOO) or BPH within the past 6 months prior to Visit 1~* Symptoms of severe over-active bladder (OAB):~  * Defined as an over-active bladder symptom score (OABSS) ≥12 at Visit 1~ * Defined as a mean of \>8 voids and a mean of ≥1 urgency episode per 24 hours at the end of the screening period prior to Visit 2~* Genito-urinary tract pathology that can in the investigator's opinion be responsible for urgency or urinary incontinence at Visit 1~* Complication of cancer or a history of cancer which has not been in remission for the last 5 years at Visit 1~* Current or a history of urologic malignancies, any lower urinary tract surgery, previous pelvic irradiation, or neoplasia at Visit 1~* History of any neurological disease affecting bladder function or muscle strength at Visit 1~* Habitual or psychogenic polydipsia based on medical history at Visit 1 or 24 hour urine output of \>2.8 L based on the voiding diary at Visit 2~* Central or nephrogenic diabetes insipidus at Visit 1~* Syndrome of inappropriate antidiuretic hormone secretion at Visit 1~* Suspicion or evidence of cardiac failure at Visit 1~* Uncontrolled hypertension at Visit 1~* Uncontrolled diabetes mellitus at Visit 1~* Hyponatraemia (serum sodium level \<135 mmol/L) at Visit 1~* Renal insufficiency at Visit 1~* Hepatic and/or biliary diseases at Visit 1~* Known or suspected hypersensitivity to desmopressin ODTs or previous desmopressin treatment for nocturia at Visit 1~* Known alcohol or substance abuse at Visit 1~* Work or lifestyle that may interfere with regular night-time sleep at Visit 1, e.g., shift workers~* Any other medical condition, laboratory abnormality, psychiatric condition, mental incapacity, or language barrier that, in the judgment of the investigator, would impair participation in the trial at Visit 1~* Use of any prohibited therapy during the trial period

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Desmopressin 25 µg (Type: EXPERIMENTAL): Desmopressin ODT
- Desmopressin 50 µg (Type: EXPERIMENTAL): Desmopressin ODT
- Placebo (Type: PLACEBO_COMPARATOR): Placebo ODT

Based on this trial design, predict the completion outcome and termination type (if applicable).